Closed · RFA-FD-14-012 · CFDA 93.103 · Discretionary

Physiologically Based Absorption and Pharmacokinetic Modeling and Simulation for Non-gastrointestinally Absorbed Drug Products In Humans

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$150K-$200K
Award range
Closed
Status
June 2, 2014
Close date
5
Expected awards

The verdict

Physiologically Based Absorption and Pharmacokinetic Modeling and Simulation for Non-gastrointestinally Absorbed Drug Products In Humans is a closed discretionary listing from Food and Drug Administration that offered $150,000 -- $200,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$150K-$200K
award range
Closed
application status
5
expected awards
93.103
CFDA program

Archived opportunity record

Physiologically Based Absorption and Pharmaco… is closed (last close June 2, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 2, 2014

Posted Mar 28 Closes Jun 2

Est. Total Funding

$1,000,000

Expected Awards

5

Instrument

Cooperative Agreement

Description

Evaluation of equivalence for complex drug products, such as locally acting drug products and non-biological complex parenteral drug products, is challenging. In general, the challenges for those drug products are to relate critical quality contributes to in vitro performance, to relate in vitro performance to in vivo performance, including drug distribution at the site of action and plasma drug distribution, and ultimately to relate in vitro drug performance to clinical performance. Physiologically based absorption and PK models capture the best current understanding of the complex interplay between product attributes and human physiology. Therefore they can aid FDA in developing regulatory science and policies in these complex areas and aid the generic industry in designing high quality products that meet public expectations for equivalence. Objectives:The objectives of this project are to develop, evaluate and improve physiologically based absorption and pharmacokinetic models for the following areas to support and facilitate generic drug guidance development, product development, and application review, in these areas.Subtopic 1: Physiologically based pharmacokinetic modeling and simulation of dermal absorptionSubtopic 2: Physiologically based pharmacokinetic modeling and simulation of ocular absorptionSubtopic 3: Physiologically based pharmacokinetic modeling and simulation for non-biological complex parenteral drug products (including liposomes, nanosuspension, micelles, microspheres, implants, and hydrogels)Subtopic 4: Physiologically based pharmacokinetic modeling and simulation of lung absorption via oral inhalationSubtopic 5: Physiologically based pharmacokinetic modeling and simulation of absorption from nasally delivered products (including nasal solutions, suspensions as well as nasal insufflation as a potential route of abuse) For each subtopic, the models should include but are not limited to formulation properties, drug substance properties, in vitro release mechanisms, physiology geometry, and microenvironment physiological parameters. The models should be based on the understanding of formulations, drug substance, physiology, mechanisms of drug delivery and mechanisms of drug transport. The final models should be able to predict drug concentration at the site of action, and drug plasma/blood concentration from various formulations.Proposals should at least include a description of the model, and model validation plans. In the proposal, applicants should indicate the formulations/drug products that will be used as model drug products for model validation and evaluation. If solutions are used in model development and validation, they should not be the only formulations used for model validation.

Wide-open applicant board · 15 Grants.gov doors

Physiologically Based Absorption and Pharmaco… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Specialist Phone 301-827-7175

What to do next

Physiologically Based Absorption and Pharmaco… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants